콘텐츠로 건너뛰기
Merck
  • Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.

Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.

Bioorganic & medicinal chemistry letters (2006-06-01)
Zhiqin Ji, Asma A Ahmed, Daniel H Albert, Jennifer J Bouska, Peter F Bousquet, George A Cunha, Keith B Glaser, Jun Guo, Junling Li, Patrick A Marcotte, Maria D Moskey, Lori J Pease, Kent D Stewart, Melinda Yates, Steven K Davidsen, Michael R Michaelides
초록

A series of isothiazolopyrimidines and isoxazolopyrimidines were synthesized and identified as potent KDR inhibitors. SAR studies led to isothiazolopyrimidine urea analogs that potently inhibit VEGFR tyrosine kinases (KDR enzymatic and cellular IC(50) values below 10 nM) as well as cKIT and TIE2. The selected compounds 8 and 13 display 56% and 48% oral bioavailability in mice, respectively.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
2-Fluoro-5-(trifluoromethyl)phenyl isocyanate, 97%